A potential unstated argument for approving capivasertib, despite its borderline data, was the fear that a rejection would kill the entire field of AKT inhibitors. This suggests that broader strategic concerns about fostering innovation can sometimes influence regulatory recommendations more than a single drug's specific risk-benefit profile.

The ADC mirvetuximab is the first drug to demonstrate an overall survival benefit for platinum-resistant ovarian cancer. This groundbreaking result establishes a higher efficacy standard that subsequent therapies will likely need to meet for regulatory approval and clinical adoption, raising the bar for future drug development.

The FDA's critique of both CREST and Potomac trials highlights that while event-free survival (EFS) endpoints were met, the lack of improvement in overall survival or prevention of muscle-invasive disease makes the risk/benefit profile questionable for an early-stage cancer, where treatment-related harm is a primary concern.

The FDA's decision to call an ODAC meeting for a trial that met its primary endpoint is a strong signal of agency concern. It indicates significant reservations about the drug's overall benefit-risk profile, particularly the modest efficacy, high toxicity, and lack of an overwhelming survival advantage.

The PEACE-3 steering committee felt its initial positive OS signal was unreliable due to non-proportional curves, despite meeting the statistical goal. This suggests a high level of self-imposed rigor, as early curve crossing can be due to statistical chance when event numbers are low, rather than a true lack of benefit.

The FDA is predicted to approve new PARP inhibitors from trials like AMPLITUDE only for BRCA-mutated patients, restricting use to where data is strongest. This contrasts with the EMA's potential for broader approvals or denials. This highlights the diverging regulatory philosophies that create different drug access landscapes in the US and Europe.

In the CREST trial, the FDA's critique heavily emphasized an overall survival hazard ratio above one. Though statistically insignificant and based on immature data, this single figure created a powerful suggestion of potential harm that overshadowed the positive primary endpoint and likely contributed to the panel's divided vote.

The failure of the PERSEVERA trial, which tested a similar drug in an unselected patient population, highlights the critical importance of SERENA-6's biomarker-driven approach. It proves that targeting only patients with the ESR1 mutation is necessary for efficacy, reinforcing the core value of precision oncology.

The FDA's current leadership appears to be raising the bar for approvals based on single-arm studies. Especially in slowly progressing diseases with variable endpoints, the agency now requires an effect so dramatic it's akin to a parachute's benefit—unmistakable and not subject to interpretation against historical data.